Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24928082 | 1.00 | CTSK (0.41) | CTSKUSP30NFKB1NFKB2RELA | |
| SCHEMBL24928078 | 1.00 | CTSK (0.41) | CTSKUSP30NFKB1NFKB2RELA | |
| SCHEMBL4641612 | 0.88 | CTSK (0.46) | CTSKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL4641615 | 0.88 | CTSK (0.46) | CTSKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL4641603 | 0.88 | CTSK (0.46) | CTSKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL18909588 | 0.86 | CTSK (0.45) | CTSKUSP30NFKB1NFKB2RELA | |
| SCHEMBL28826192 | 0.86 | SSTR4 (0.47) | CTSKNFKB1NFKB2RELACA1 | |
| SCHEMBL14908035 | 0.83 | CTSK (0.43) | CTSKUSP30NFKB1NFKB2RELA | |
| SCHEMBL14908041 | 0.83 | CTSK (0.43) | CTSKUSP30NFKB1NFKB2RELA | |
| SCHEMBL23260090 | 0.83 | CTSK (0.40) | CTSKUSP30NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025037229-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS AG (CH) | 2025-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | MAPK1, MAP3K1, MAPK6 | CTSK 1188/4885USP30 2341/4885NFKB1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.